A Guildford-based healthcare business, committed to supporting people with diabetes, has teamed up with the NHS to provide “life-changing” continuous glucose monitors to everyone living with type 1 diabetes in the UK.
GlucoRx rolls out free continuous glucose monitors (CGMs) to NHS patients with type 1 diabetes with 14 days use. The GlucoRx AiDEX CGM has been available on the Drug tariff since April 1, 2022.
Following the latest NICE guidelines, every person living with the condition is now eligible for a CGM – a wearable sensor allowing people to check their glucose levels with a one-second scan.
According to GlucoRx, the product combines accuracy and cost-efficiency in price compared to other CGMs.
Chris Chapman, a chief operating officer of GlucoRx, said: “We are delighted that our life-changing CGM devices are the first CGMs to be available on prescription for every NHS patient with type 1 diabetes.
“It is an honour to work with the NHS on such a big project which will improve the quality of life for thousands of people with the condition.”
GlucoRx AiDEX CGM achieved drug tariff status earlier this month, meaning it is now approved for use by the NHS.
“Achieving drug tariff status now allows us to make a bigger difference within the world of diabetes,” said Chris. He added: “We pride ourselves on prioritising patient care and enhancing the health outcomes for people living with type 1 diabetes.
"To date, more than 1,000 GlucoRx CGM’s have been sold, with users branding the GlucoRx AiDEX CGM as “super easy to use” and “extremely accurate”.
Research presented at the Diabetes UK Professional Conference 2022 revealed that flash monitoring not only helps to improve blood glucose levels in people with type 1 diabetes, but also has a positive effect on their quality of life.
Currently, NHS England spends roughly £10 billion a year on diabetes – around 10 per cent of its entire budget.
According to the NHS, tools like continuous glucose monitoring, which help people better manage their condition and reduce associated illness and hospitalisations, will reduces costs in the long run.
In the past 10 years, GlucoRx has saved the NHS around £350 million by reaching out to Clincal Commissioning Groups across the UK.
